BIIB
CALLS ▲Biogen Inc.
$209.23
+1.76%delayed
News – · Trend ▲ · above call trigger ▲
Expected move (1d)
▼ $201.08to$217.38 ▲
ATR ±$8.15 (+3.89%)Implied ±$5.88 (+2.81%)
Entry Reference
Price / prev close$209.23 / $205.61
Day range$206.26 – $218.53
52-wk range$124.56 – $219.72(89%)
Volume vs avg1.88×
ATR (14d)$8.15
MA 8 / 21$202.33 / $204.11
MA 50 / 200$199.95 / $182.75
Call ▲ / Put ▼ trigger$207.53 / $203.69
+1 / +2 ATR$217.38 / $225.52
-1 / -2 ATR$201.08 / $192.94
Support: 205.97 203.45 199.80
Resistance: 215.79 219.72
Near-the-money contracts
exp 2026-07-31Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 202.5 | $7.95 | 72% | 0.75 | -0.96 | 105 |
| 205 | $5.45 | 63% | 0.69 | -0.93 | 128 |
| 207.5 | $4.05 | 68% | 0.58 | -1.10 | 10 |
| 210 | $2.63 | 64% | 0.48 | -1.07 | 35 |
| 212.5 | $1.88 | 65% | 0.38 | -1.03 | 5 |
| 215 | $1.57 | 68% | 0.29 | -0.96 | 57 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 202.5 | $0.80 | 52% | -0.17 | -0.54 | 2 |
| 205 | $2.10 | 67% | -0.32 | -0.98 | 42 |
| 207.5 | $2.33 | 63% | -0.41 | -0.99 | 5 |
| 210 | $3.25 | 62% | -0.52 | -1.01 | 9 |
| 212.5 | $4.60 | 61% | -0.63 | -0.94 | 1 |
| 215 | $6.65 | 64% | -0.72 | -0.86 | 7 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- Biogen Inc. Q2 2026 Earnings Call Summary2h ago
- Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views4h ago
- Why Biogen Stock Is Resisting a Market Downturn After Earnings5h ago
- Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript6h ago
- Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised7h ago
- Biogen Q2 Earnings Call Highlights8h ago
- Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates8h ago
- Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher9h ago
- Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY20269h ago
- Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story10h ago
- Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates10h ago
- Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)10h ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.